Blindness risk double in men

Article

Despite the higher rate of prevalence in women, it is men who are more likely to suffer severe vision loss as a result of idiopathic intracranial hypertension (IIH), according to study results published online ahead of print by Neurology.

Despite the higher rate of prevalence in women, it is men who are more likely to suffer severe vision loss as a result of idiopathic intracranial hypertension (IIH), according to study results published online ahead of print by Neurology.

Beau B. Bruce, MD of Emory University, Atlanta, US and colleagues conducted a medical record review of IIH patients (n=721) in three hospitals. Subjects, who underwent neuro-ophthalmologic testing, were segregated for gender (male, n=66; female, n=655) and a statistical comparison was undertaken.

The men included in the study were older and more likely to suffer from sleep apnoea than the women: 37 vs 28 years and 24% vs 4%, respectively. As a first symptom of IIH, men tended to report visual disturbance and women, headaches. At the final follow-up point, mean visual acuity was worse for men than for women. After logistical regression analysis, the researchers determined that the 2.1 times increased chance of men developing severe visual loss when compared with women was correlated to sex.

The team therefore concluded that men are more than twice as likely to sustain severe vision loss, to the extent of being declared legally blind, than women, which may be related to the differences in the symptom profile presented by the different genders.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.